AdAlta (ASX:1AD) is bringing cellular immunotherapy products from Asian to western markets to drive value creation.

While genetic testing rates for advanced ovarian cancer have increased, gaps in physician understanding and confidence in interpreting results may limit optimal biomarker-driven treatment and patient ...

New data showed that prior malignancy may influence survival outcomes in patients with metastatic colorectal cancer, ...

Life's Crucial 9 (LC9), a recently proposed method for assessing cardiovascular health, has a strong negative correlation with overactive bladder (OAB), which is partially mediated by the ...